{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:03:49Z","timestamp":1779930229129,"version":"3.53.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04298-9","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:38:09Z","timestamp":1776397089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of single-inhaler triple therapies for chronic obstructive pulmonary disease: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"4298_CR1","doi-asserted-by":"crossref","unstructured":"Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J 2019;53(5):1900164.","DOI":"10.1183\/13993003.00164-2019"},{"issue":"1","key":"4298_CR2","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12890-025-03823-6","volume":"25","author":"Y Li","year":"2025","unstructured":"Li Y, Li J, Yang H, Zhang Y. Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials. BMC Pulmonary Med 2025. 2025;25(1):345.","journal-title":"BMC Pulmonary Med 2025"},{"key":"4298_CR3","unstructured":"Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2025 report) [EB\/OL].[2024-12-01]. https:\/\/goldcopd.org\/2025-gold-report\/. 2025."},{"issue":"1","key":"4298_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/17476348.2020.1816830","volume":"15","author":"L Calzetta","year":"2021","unstructured":"Calzetta L, Ritondo BL, de Marco P, Cazzola M, Rogliani P. Evaluating triple ICS\/LABA\/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies. Expert Rev Respir Med. 2021;15(1):143\u201352.","journal-title":"Expert Rev Respir Med"},{"issue":"1","key":"4298_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/resp.12646","volume":"21","author":"SD Lee","year":"2016","unstructured":"Lee SD, Xie CM, Yunus F, Itoh Y, Ling X, Yu WC, et al. Efficacy and tolerability of budesonide\/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia. Respirol (Carlton Vic). 2016;21(1):119\u201327.","journal-title":"Respirol (Carlton Vic)"},{"issue":"9","key":"4298_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.rmed.2015.06.006","volume":"109","author":"TM Siler","year":"2015","unstructured":"Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A. Efficacy and safety of umeclidinium added to fluticasone furoate\/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir Med. 2015;109(9):1155\u201363.","journal-title":"Respir Med"},{"issue":"10048","key":"4298_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavli\u0161ov\u00e1 I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet (London England). 2016;388(10048):963\u201373.","journal-title":"Lancet (London England)"},{"issue":"10125","key":"4298_CR8","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","volume":"391","author":"A Papi","year":"2018","unstructured":"Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet (London England). 2018;391(10125):1076\u201384.","journal-title":"Lancet (London England)"},{"issue":"1","key":"4298_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12931-021-01683-2","volume":"22","author":"J Zheng","year":"2021","unstructured":"Zheng J, Baldi S, Zhao L, Li H, Lee KH, Singh D, et al. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respir Res. 2021;22(1):90.","journal-title":"Respir Res"},{"issue":"1","key":"4298_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12890-018-0724-3","volume":"18","author":"M Humenberger","year":"2018","unstructured":"Humenberger M, Horner A, Labek A, Kaiser B, Frechinger R, Brock C, et al. Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD). BMC Pulm Med. 2018;18(1):163.","journal-title":"BMC Pulm Med"},{"issue":"1","key":"4298_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12931-020-01360-w","volume":"21","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Brown N, Compton C, Corbridge TC, Dorais K, Fogarty C, et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir Res. 2020;21(1):131.","journal-title":"Respir Res"},{"key":"4298_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/COPD.S234823","volume":"15","author":"S Zhang","year":"2020","unstructured":"Zhang S, King D, Rosen VM, Ismaila AS. Impact of Single Combination Inhaler versus Multiple Inhalers to Deliver the Same Medications for Patients with Asthma or COPD: A Systematic Literature Review. Int J Chronic Obstr Pulm Dis. 2020;15:417\u201338.","journal-title":"Int J Chronic Obstr Pulm Dis"},{"issue":"1","key":"4298_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12931-018-0724-0","volume":"19","author":"PR Bremner","year":"2018","unstructured":"Bremner PR, Birk R, Brealey N, Ismaila AS, Zhu CQ, Lipson DA. Single-inhaler fluticasone furoate\/umeclidinium\/vilanterol versus fluticasone furoate\/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study. Respir Res. 2018;19(1):19.","journal-title":"Respir Res"},{"issue":"10082","key":"4298_CR14","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/S0140-6736(17)30188-5","volume":"389","author":"J Vestbo","year":"2017","unstructured":"Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet (London England). 2017;389(10082):1919\u201329.","journal-title":"Lancet (London England)"},{"issue":"10","key":"4298_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"GT Ferguson","year":"2018","unstructured":"Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, et al. Triple therapy with budesonide\/glycopyrrolate\/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respiratory Med. 2018;6(10):747\u201358.","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"4298_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa1916046","volume":"383","author":"KF Rabe","year":"2020","unstructured":"Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35\u201348.","journal-title":"N Engl J Med"},{"key":"4298_CR17","doi-asserted-by":"crossref","unstructured":"Salvi S, Balki A, Krishnamurthy S, Panchal S, Patil S, Kodgule R et al. Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial. ERJ open Res 2021;7(3):00255\u20132021.","DOI":"10.1183\/23120541.00255-2021"},{"key":"4298_CR18","doi-asserted-by":"crossref","unstructured":"Lai CC, Chen CH, Chen KH, Wang CY, Huang TM, Wang YH et al. The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life (Basel, Switzerland). 2022;12(2):173.","DOI":"10.3390\/life12020173"},{"issue":"6","key":"4298_CR19","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1007\/s12325-021-01703-z","volume":"38","author":"A Bourdin","year":"2021","unstructured":"Bourdin A, Molinari N, Ferguson GT, Singh B, Siddiqui MK, Holmgren U, et al. Efficacy and Safety of Budesonide\/Glycopyrronium\/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Adv therapy. 2021;38(6):3089\u2013112.","journal-title":"Adv therapy"},{"issue":"6","key":"4298_CR20","doi-asserted-by":"publisher","first-page":"2956","DOI":"10.1007\/s12325-020-01311-3","volume":"37","author":"GT Ferguson","year":"2020","unstructured":"Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, et al. Efficacy of Budesonide\/Glycopyrronium\/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid\/Long-Acting Muscarinic Antagonist\/Long-Acting \u03b2(2)-Agonist (ICS\/LAMA\/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Adv therapy. 2020;37(6):2956\u201375.","journal-title":"Adv therapy"},{"issue":"9","key":"4298_CR21","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1007\/s12325-022-02231-0","volume":"39","author":"AS Ismaila","year":"2022","unstructured":"Ismaila AS, Haeussler K, Czira A, Youn JH, Malmen\u00e4s M, Risebrough NA, et al. Fluticasone Furoate\/Umeclidinium\/Vilanterol (FF\/UMEC\/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis. Adv therapy. 2022;39(9):3957\u201378.","journal-title":"Adv therapy"},{"issue":"1","key":"4298_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.arbres.2023.10.006","volume":"60","author":"JA Riesco Miranda","year":"2024","unstructured":"Riesco Miranda JA, Calle Rubio M, D\u00edaz P\u00e9rez D, L\u00f3pez-Campos JL, Trigueros Carrero JA, Celli B. Efficacy and Safety of Single-inhaler Triple Therapy Containing Dual Bronchodilator With Corticosteroids Compared to Monotherapy, Dual Therapy, or Open Triple Therapy in Moderate\/Severe COPD: A Systematic Literature Review. Arch Bronconeumol. 2024;60(1):55\u20138.","journal-title":"Arch Bronconeumol"},{"key":"4298_CR23","doi-asserted-by":"crossref","unstructured":"Jones PW, Quirk FH, Baveystock CM. The St George\u2019s Respiratory Questionnaire. Respiratory medicine 1991;85 Suppl B:25\u201331.","DOI":"10.1016\/S0954-6111(06)80166-6"},{"issue":"6","key":"4298_CR24","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321\u20137.","journal-title":"Am Rev Respir Dis"},{"issue":"10","key":"4298_CR25","first-page":"Ed000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10(10):Ed000142.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"4298_CR26","first-page":"905","volume":"15","author":"A Chaimani","year":"2015","unstructured":"Chaimani A, Salanti G. Visualizing Assumptions and Results in Network Meta-analysis. Netw Graphs Package. 2015;15(4):905\u201350.","journal-title":"Netw Graphs Package"},{"issue":"2","key":"4298_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins JP, Jackson D, Barrett JK, Lu G, Ades AE, White IR. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res synthesis methods. 2012;3(2):98\u2013110.","journal-title":"Res synthesis methods"},{"key":"4298_CR28","doi-asserted-by":"crossref","unstructured":"Kots M, Georges G, Guasconi A, Vogelmeier C. S26 Effect of single-inhaler extrafine beclometasone\/formoterol\/glycopyrronium pMDI (BDP\/FF\/GB) compared with two-inhaler fluticasone furoate\/vilanterol DPI\u2009+\u2009tiotropium DPI (FLF\/VIL\u2009+\u2009TIO) triple therapy on health-related quality of life (HRQoL) in patients with COPD: The TRISTAR study. 2021;76(2):A20.","DOI":"10.1136\/thorax-2021-BTSabstracts.32"},{"issue":"4","key":"4298_CR29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","volume":"196","author":"DA Lipson","year":"2017","unstructured":"Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017;196(4):438\u201346.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"4298_CR30","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","volume":"378","author":"DA Lipson","year":"2018","unstructured":"Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671\u201380.","journal-title":"N Engl J Med"},{"key":"4298_CR31","doi-asserted-by":"publisher","first-page":"k4388","DOI":"10.1136\/bmj.k4388","volume":"363","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Zhu J, Liu Y, Lai W, Lin C, Qiu K, et al. Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ (Clinical Res ed. 2018;363:k4388.","journal-title":"BMJ (Clinical Res ed"},{"key":"4298_CR32","doi-asserted-by":"crossref","unstructured":"Cazzola M, Rogliani P, Calzetta L, Matera MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018;52(6):1801586.","DOI":"10.1183\/13993003.01586-2018"},{"issue":"4","key":"4298_CR33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.chest.2018.12.016","volume":"155","author":"L Calzetta","year":"2019","unstructured":"Calzetta L, Cazzola M, Matera MG, Rogliani P. Adding a LAMA to ICS\/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD. Chest. 2019;155(4):758\u201370.","journal-title":"Chest"},{"issue":"7","key":"4298_CR34","first-page":"631","volume":"100","author":"HW Lee","year":"2021","unstructured":"Lee HW, Kim HJ, Jang EJ, Lee CH. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid\/Long-Acting Muscarinic Antagonist\/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis. Respir Int Rev Thorac Dis. 2021;100(7):631\u201343.","journal-title":"Respir Int Rev Thorac Dis"},{"key":"4298_CR35","doi-asserted-by":"crossref","unstructured":"Rohde G, Vogelmeier CF, Beeh KM, Kardos P, Paulsson T, Watz H et al. TETRIS - Prospective study to observe clinical outcomes of triple therapy in COPD patients: up to 12 months interim analysis. Respiratory Med 2026 Jan:251:108597.","DOI":"10.1016\/j.rmed.2025.108597"},{"issue":"1","key":"4298_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/15412555.2019.1593342","volume":"16","author":"D Epstein","year":"2019","unstructured":"Epstein D, Barak-Corren Y, Isenberg Y, Berger G. Clinical Decision Support System: A Pragmatic Tool to Improve Acute Exacerbation of COPD Discharge Recommendations. Copd. 2019;16(1):18\u201324.","journal-title":"Copd"},{"issue":"1","key":"4298_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/15412555.2022.2035705","volume":"19","author":"S Suissa","year":"2022","unstructured":"Suissa S, Dell\u2019Aniello S, Ernst P. Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. Copd. 2022;19(1):109\u201317.","journal-title":"Copd"},{"key":"4298_CR38","first-page":"e080409","volume":"387","author":"WB Feldman","year":"2024","unstructured":"Feldman WB, Suissa S, Kesselheim AS, Avorn J, Russo M, Schneeweiss S, et al. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ (Clinical Res ed). 2024;387:e080409.","journal-title":"BMJ (Clinical Res ed)"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04298-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04298-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:15:21Z","timestamp":1779927321000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04298-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4298"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04298-9","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethics statement is not applicable because this study is based exclusively on published literature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"247"}}